Lonza Group AG (VIE:LONN)
Austria flag Austria · Delayed Price · Currency is EUR
517.20
-6.00 (-1.15%)
Last updated: Apr 29, 2026, 11:00 AM CET

Lonza Group AG Company Description

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.

Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms.

The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA.

Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Lonza Group AG
Country Switzerland
Founded 1897
Industry Chemicals and Allied Products
Employees 20,000
CEO Wolfgang Wienand

Contact Details

Address:
Muenchensteinerstrasse 38
Basel, 4002
Switzerland
Phone 41 61 316 81 11
Website lonza.com

Stock Details

Ticker Symbol LONN
Exchange Vienna Stock Exchange
Fiscal Year January - December
Reporting Currency CHF
SIC Code 2800

Key Executives

Name Position
Wolfgang Wienand Chief Executive Officer
Philippe Deecke Chief Financial Officer
Jason Berndt Chief Operating Officer
Daniel Buchta Head of Investor Relations